Suppr超能文献

静脉血栓形成的抗凝治疗持续时间。

Duration of anticoagulant treatment for venous thrombosis.

作者信息

Raskob G E

机构信息

Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA.

出版信息

Curr Opin Pulm Med. 1997 Jul;3(4):286-90. doi: 10.1097/00063198-199707000-00009.

Abstract

Patients with deep-vein thrombosis require long-term anticoagulant treatment to prevent recurrent venous thromboembolism. Anticoagulant treatment should be continued for at least 3 months in patients with a first-episode of proximal deep-vein thrombosis. In patients with a second-episode of venous thromboembolism, treatment should probably be continued for at least 1 year, because stopping treatment at 3 to 6 months is associated with a high rate of recurrent venous thromboembolism. Indefinite treatment may be indicated in patients with a second-episode of venous thromboembolism, but further clinical trials are required to clarify the risk and benefit of indefinite treatment. Further clinical trials are also required to determine if a longer course of treatment is indicated for subgroups of patients based on clinical characteristics and laboratory features (such as those with idiopathic thrombosis versus postoperative thrombosis, and those with or without identifiable molecular markers of a high risk of recurrent venous thromboembolism such as the factor V Leiden gene mutation).

摘要

深静脉血栓形成患者需要长期抗凝治疗以预防复发性静脉血栓栓塞。首次发生近端深静脉血栓形成的患者,抗凝治疗应持续至少3个月。对于第二次发生静脉血栓栓塞的患者,治疗可能应持续至少1年,因为在3至6个月时停止治疗与静脉血栓栓塞复发率高相关。第二次发生静脉血栓栓塞的患者可能需要无限期治疗,但需要进一步的临床试验来阐明无限期治疗的风险和益处。还需要进一步的临床试验来确定是否根据临床特征和实验室特征(如特发性血栓形成与术后血栓形成的患者,以及有无可识别的复发性静脉血栓栓塞高风险分子标志物如因子V莱顿基因突变的患者)为患者亚组指示更长疗程的治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验